Chester County News and Community Website
JENKINTOWN, PA — SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both …
SFA Therapeutics Reports Promising Phase 1b Results for Oral Psoriasis Treatment Read More JENKINTOWN, PA — SFA Therapeutics, Inc., a biotech firm specializing in autoimmune diseases and hepatocellular carcinoma, announced a significant expansion of its intellectual property this week. The company secured a …
SFA Therapeutics Strengthens Patent Portfolio for Key Drug Candidates Read More JENKINTOWN, PA — SFA Therapeutics, Inc. recently appointed Dr. Ananda Gubbi, Ph.D., as Director of Biostatistics, a strategic move to bolster the company’s drug development capabilities. With over 25 years of …
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development Read More JENKINTOWN, PA — SFA Therapeutics, Inc. has named James Kirwin, MBA, as its new Chief Operating Officer. Kirwin will spearhead clinical trial agreements, oversee collaborations with regulatory teams, and manage …
SFA Therapeutics Appoints James Kirwin as Chief Operating Officer Read More JENKINTOWN, PA — SFA Therapeutics, Inc. recently announced the completion of patient enrollment for cohort 2 in its Phase 1b clinical trial of SFA-002, aimed at treating mild-to-moderate chronic plaque …
SFA Therapeutics Completes Key Phase 1b Trial Enrollment for Psoriasis Treatment Read More